FibroGen Inc. (FGEN)
FibroGen Statistics
Share Statistics
FibroGen has 100.92M shares outstanding. The number of shares has increased by 1.45% in one year.
Shares Outstanding | 100.92M |
Shares Change (YoY) | 1.45% |
Shares Change (QoQ) | 0.15% |
Owned by Institutions (%) | 36.06% |
Shares Floating | 93.8M |
Failed to Deliver (FTD) Shares | 20K |
FTD / Avg. Volume | 0.56% |
Short Selling Information
The latest short interest is 4.32M, so 4.29% of the outstanding shares have been sold short.
Short Interest | 4.32M |
Short % of Shares Out | 4.29% |
Short % of Float | 4.62% |
Short Ratio (days to cover) | 3.27 |
Valuation Ratios
The PE ratio is -0.35 and the forward PE ratio is -1.29. FibroGen's PEG ratio is 0.01.
PE Ratio | -0.35 |
Forward PE | -1.29 |
PS Ratio | 1.79 |
Forward PS | 0.1 |
PB Ratio | -0.29 |
P/FCF Ratio | -0.38 |
PEG Ratio | 0.01 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for FibroGen.
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.47, with a Debt / Equity ratio of -0.4.
Current Ratio | 1.47 |
Quick Ratio | 1.45 |
Debt / Equity | -0.4 |
Debt / EBITDA | -0.51 |
Debt / FCF | -0.53 |
Interest Coverage | -18.24 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity | n/a |
Return on Assets | n/a |
Return on Invested Capital | n/a |
Revenue Per Employee | $131.65K |
Profits Per Employee | $-680.44K |
Employee Count | 225 |
Asset Turnover | 0.14 |
Inventory Turnover | 4.93 |
Taxes
Income Tax | -269K |
Effective Tax Rate | 0.18% |
Stock Price Statistics
The stock price has increased by -79.59% in the last 52 weeks. The beta is 0.83, so FibroGen's price volatility has been higher than the market average.
Beta | 0.83 |
52-Week Price Change | -79.59% |
50-Day Moving Average | 0.45 |
200-Day Moving Average | 0.51 |
Relative Strength Index (RSI) | 38.31 |
Average Volume (20 Days) | 3.56M |
Income Statement
In the last 12 months, FibroGen had revenue of 29.62M and earned -153.1M in profits. Earnings per share was -1.53.
Revenue | 29.62M |
Gross Profit | 14.06M |
Operating Income | -150.42M |
Net Income | -153.1M |
EBITDA | -142.43M |
EBIT | -145.12M |
Earnings Per Share (EPS) | -1.53 |
Balance Sheet
The company has 50.48M in cash and 73.09M in debt, giving a net cash position of -22.61M.
Cash & Cash Equivalents | 50.48M |
Total Debt | 73.09M |
Net Cash | -22.61M |
Retained Earnings | -1.89B |
Total Assets | 214.53M |
Working Capital | 63.2M |
Cash Flow
In the last 12 months, operating cash flow was -138M and capital expenditures -266K, giving a free cash flow of -138.26M.
Operating Cash Flow | -138M |
Capital Expenditures | -266K |
Free Cash Flow | -138.26M |
FCF Per Share | -1.38 |
Margins
Gross margin is 47.47%, with operating and profit margins of -507.8% and -516.86%.
Gross Margin | 47.47% |
Operating Margin | -507.8% |
Pretax Margin | -517.76% |
Profit Margin | -516.86% |
EBITDA Margin | -480.83% |
EBIT Margin | -507.8% |
FCF Margin | -466.78% |
Dividends & Yields
FGEN does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | n/a |
FCF Yield | n/a |
Analyst Forecast
The average price target for FGEN is $10, which is 3233.3% higher than the current price. The consensus rating is "Buy".
Price Target | $10 |
Price Target Difference | 3233.3% |
Analyst Consensus | Buy |
Analyst Count | 1 |
Scores
Altman Z-Score | -14.08 |
Piotroski F-Score | 2 |